Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EUK-189 is a synthetic, lipophilic salen-manganese complex that functions as a catalytic scavenger of reactive oxygen species (ROS). Developed by Eukarion, Inc. (later acquired by Proteome Systems), it is designed to mimic the activity of two key endogenous antioxidant enzymes: superoxide dismutase (SOD) and catalase. Unlike stoichiometric antioxidants, EUK-189 acts catalytically, allowing it to neutralize multiple ROS molecules without being consumed. Its lipophilic nature enables it to penetrate cellular membranes and the blood-brain barrier, providing neuroprotective effects. Preclinical research has demonstrated that EUK-189 can reverse age-related cognitive deficits and reduce oxidative stress in the brain. It has been investigated for its therapeutic potential in various oxidative stress-related conditions, including neurodegenerative diseases like Parkinson's disease and the mitigation of radiation-induced injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EUK-189.